[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"emotional-processing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:emotional-processing":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,77,133,158,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100613512","phase-4-dual-orexin-antagonism-and-emotion-and-affective-processing-study-100613512",false,"NCT07267559","Dual Orexin Antagonism and Emotion and Affective Processing Study","An Investigation of the Effects of Dual Orexin Antagonism on Emotional Processing and Learning in Healthy Individuals","DOREA","Inclusion Criteria:\n\n* Adult participant, aged 18 to 40 years\n* Willing and able to give informed consent for participation in the trial\n* Able to follow study procedures as laid out in the participant information sheet\n* Able to read and understand English\n* Willing to avoid drinking alcohol, using recreational drugs, drinking grapefruit juice 24 hours before and after the study visit\n* Willing to avoid driving or engaging in any activities requiring full alertness (e.g. cycling or operating heavy machinery) until the morning after the study visit day.\n* Able to complete computer tasks without eye glasses even if uses correction regularly\n\nExclusion Criteria:\n\n1. History of, receiving or seeking treatment for any sleep or circadian rhythm disorder or positive in screening questionnaires.\n2. History of, receiving or seeking treatment for any clinically significant mental health condition (including but not limited to schizophrenia, psychosis, bipolar affective disorder, major depressive disorder, obsessive compulsive disorder, post-traumatic stress disorder) or positive in screening questionnaires.\n3. History of, or current medical condition(s) which might increase the risk of oral administration of daridorexant, including:\n\n   * ADHD requiring treatment with stimulants or other centrally-acting drugs\n   * Neurological problems, including traumatic brain injury, epilepsy, Central Nervous System tumours or other severe neurological problems (e.g. Parkinson's disease; blackouts requiring hospitalisation)\n   * Current Asthma, Chronic Obstructive Pulmonary Disease, emphysema or any medical condition that affects the lungs or breathing\n   * Mild to severe hepatic impairment (Child-Pugh class A-C)\n   * Severe renal disease\n   * Severe gastrointestinal problems\n   * History of, or current medical condition(s) which, in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study\n4. Pregnancy (as determined by urine pregnancy test taken during screening visit), intention to become pregnant or breastfeeding during the study or over the following six months.\n5. Body mass index (BMI) below 18 or above 30kg\u002Fm2.\n6. Current or past history of drug or alcohol dependency.\n7. Regular alcohol consumption of more than 21 units per week or use of recreational drugs or performance-enhancing drugs (e.g. cannabis, cocaine, amphetamines) within past three months.\n8. Excessive caffeine consumption, i.e., consumption higher than 400mg a day of caffeine. This corresponds to more than 4 cups of brewed coffee, 6 espressos or filtered coffees, 9 cups of black tea, 10 cans of cola, or two \"energy shot\" drinks.\n9. Smoking more than 5 cigarettes per day (or other nicotine replacement equivalent, including vaping on average more than 50 puffs a day).\n10. Current or recent (past two months) use of any medication or medical devices (e.g. implanted neurostimulator) that affect brain function for the exception of contraceptives (pill, the Depo-Provera injection or the progesterone implant). This includes drugs that cause sedation (e.g. benzodiazepines, opioids, tricyclic antidepressants or sedative antipsychotics) or antihistamines.\n11. Current use of any medications at risk of interaction with daridorexant; in particular:\n\n    * strong or moderate CYP3A inhibitors (e.g. strong inhibitors - itraconazole, clarithromycin, ritonavir, grapefruit juice; moderate inhibitors - fluconazole, verapamil, diltiazem, erythromycin, ciprofloxacin, cyclosporine)\n    * strong or moderate CYP3A inducers (e.g. of strong inducers - rifampicin, carbamazepine, St. John's wort; moderate inducers - bosentan, efavirenz, etravirine, modafinil)\n    * Gastric pH-modifiers (e.g. famotidine and proton pump inhibitors such as omeprazole)\n    * P-gp transporters (e.g. dabigatran, digoxin)\n12. Inability to ingest up to 95mg of lactose.\n13. Previous participation in any other drug study or sleep intervention study in the last three months.\n14. Previous participation in any other study by the Psychopharmacology and Emotion Research lab (Department of Psychiatry, University of Oxford) or which uses the same computer tasks in the last 6 months\n15. Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator.",true,"ALL","18 Years","40 Years",{"count":22,"type":23},62,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","In this study, the investigators will examine the effects of blocking the orexin system on human behaviour and brain function using daridorexant, a medication that inhibits orexin activity. Orexin is a brain chemical involved in regulating sleep, emotion, motivation, and stress responses, which are often disrupted in mental health disorders. Healthy volunteers will be randomly assigned to receive a single dose of daridorexant or placebo in a double-blind design. Participants will then complete behavioural and cognitive tasks assessing emotional processing, aversive learning, and executive function. The study aims to clarify the role of orexin in emotional and cognitive processes relevant to conditions such as depression and anxiety.",[29,30,31],"Learning","Cognitive Functioning","Emotional Processing",[33,34,35,36,29,37],"Drug","Orexin","Hypocretin","Healthy volunteers","Cognition","RECRUITING","2026-03-16",{"date":41,"type":42},"2026-03-19","ACTUAL",{"date":44,"type":42},"2025-10-01",{"date":46,"type":23},"2026-10-01",{"name":48,"class":49},"University of Oxford","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100594252","early-phase-1-combined-blood-pressure-medication-and-activity-scheduling-for-low-mood-100594252","NCT07017023","Combined Blood Pressure Medication and Activity Scheduling for Low Mood","Cognitive Effects of Losartan-augmented Behavioural Activation in Anhedonia","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Aged 18-65 years\n* Self-reported low levels of positive mood\n* Sufficient written and spoken English skills to understand study procedures\n* Normal or corrected to normal vision and hearing\n* Access to a computer and reliable internet connection\n\nExclusion Criteria:\n\n* Antidepressant treatment or medication in last three months\n* Currently receiving cognitive-behavioural therapy with behavioural activation\n* History of psychosis or bipolar disorder\n* History of substance dependence\n* Use of illegal drugs in last 3 months\n* First-degree relative with history of psychosis or bipolar disorder\n* Current or past hospitalisation for mental health reasons\n* BDI-II score \\>30\n* Judged to be currently at clinical risk of suicide\n* Past suicide attempt\n* CNS-medication last 6 weeks (including in another study)\n* Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medic\n* Current blood pressure or other heart medication\n* Diagnosis of intravascular fluid depletion or dehydration\n* History of angioedema\n* Impaired kidney function (based on self-report)\n* Very low blood pressure following established definitions (at least three consecutive measurements of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F60 mmHg (in accordance with established standard definitions: https:\u002F\u002Fwww.nhs.uk\u002Fcond...-pressure-hypotension\u002F)\n* Current diagnosis of a developmental disorder (e.g. ADHD, Tourette's syndrome, severe learning disability) according to self-report, where in the opinion of the study team such difficulties would likely interfere with compliance or task performance\n* Current diagnosis of a neurological disorder (e.g. epilepsy, MS) according to self-report\n* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may put the participant at risk when participating, or may influence compliance or task performance\n* Pregnancy (urine pregnancy test during Baseline Visit), breast feeding or plans to become pregnant during study participation\n* Heavy use of cigarettes (smoke \\> 20 cigarettes per day)\n* Severe lactose intolerance (due to losartan containing some lactose monohydrate)","65 Years",{"count":60,"type":23},76,[62],"EARLY_PHASE1","This study explores the effects of 7-day losartan (50mg) versus placebo with brief behavioural activation on emotional processing in young volunteers low in positive mood",[31,65],"Mood",[67,68],"emotional processing","mood","2025-07-23",{"date":71,"type":42},"2025-07-24",{"date":73,"type":42},"2025-07-08",{"date":75,"type":23},"2026-12-31",{"name":48,"class":49},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":90,"conditions":91,"keywords":108,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":50},"100597441","therapeutic-writing-for-adults-suffering-from-chronic-pain-and-comorbid-mental-health-disorders-100597441","NCT07058532","Therapeutic Writing for Adults Suffering From Chronic Pain and Comorbid Mental Health Disorders","Therapeutic Writing Intervention in Pain Rehabilitation","TWfCP&MH","Inclusion Criteria:\n\n* Adult women (18 years or older), assigned female at birth and self-identify as women\n* Diagnosed with or experience of chronic, widespread (non-cancer) pain lasting at least two years\n* Diagnosed with or living with one or more mild mental health disorders (e.g., anxiety, mild depression), without current or past severe psychiatric conditions\n* Diagnosed with or experience of nociplastic pain (e.g., fibromyalgia)\n* Not currently using medications that may impair cognitive functioning (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Able to attend approximately 11 in-person visits over a 3-month period\n* Willing and able to participate in a structured therapeutic writing intervention\n* Purposefully selected to reflect a range of lived experiences relevant to the study's aims\n\nExclusion Criteria:\n\n* Presence of severe mental health disorders (e.g., schizophrenia, bipolar disorder, severe depression, or other psychotic conditions)\n* Use of medications known to impair memory, attention, or decision-making (e.g., benzodiazepines, anticholinergics, opioids, antipsychotics)\n* Participation in other concurrent treatments that may influence study outcomes\n* Cognitive limitations that would hinder meaningful engagement in the writing intervention\n* Individuals not assigned female at birth or who do not identify as women","FEMALE",{"count":87,"type":23},5,[89],"NA","The goal of this observational study is to understand the effects and experiences of therapeutic writing interventions in adult women with chronic pain and co-occurring mental health conditions. The main questions it aims to answer are:\n\nCan therapeutic writing help relieve chronic pain and emotional distress?\n\nHow does writing support emotional processing, regulation, and meaning-making during rehabilitation?\n\nParticipants will take part in a two-part writing intervention involving:\n\nGuided writing exercises that focus on emotional processing, emotion regulation, and creating meaning.\n\nIndividual interviews after the writing sessions to explore their experiences.\n\nThe study uses qualitative analysis methods-phenomenology and logotherapy-to better understand how these writing interventions may support recovery, improve well-being, and offer non-pharmacological tools for managing chronic pain and mental health challenges.",[92,93,94,95,96,97,98,99,31,100,101,102,103,104,105,106,107],"Chronic Pain","Mental Health Disorder","Psychiatric &Amp;Amp;or Mood Disorder","Psychiatric Comorbidities","Psychiatric Diagnosis","Emotional Pain","Emotional Distress","Emotion Regulation","Meaning of Life","Meaning Made","Meaning of Life and Life Satisfaction","Depressive Disorder","Anxiety Disorders","Sleep Disorder","Comorbid Depression","Process, Acceptance",[109,110,111,112,113,114,115,116,117,118,119,120,121,122],"Therapeutic writing","Chronic pain","Mental health disorders","Psychiatric disorders","Emotion regulation","Emotional processing","Meaning-making","Non-pharmacological intervention","Logotherapy","Phenomenological analysis","Psychosocial rehabilitation","Pain management","Pain coping","Creative writing","NOT_YET_RECRUITING","2025-06-30",{"date":126,"type":42},"2025-07-10",{"date":128,"type":23},"2025-08",{"date":130,"type":23},"2026-04",{"name":132,"class":49},"Toni Salikka",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":17,"sex":18,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":50},"100565025","early-phase-1-losartan-and-emotional-processing-in-young-people-100565025","NCT06636812","Losartan and Emotional Processing in Young People","The Effects of Single-dose Losartan on the Processing of Emotional Information in Healthy Adolescents: a Randomised Controlled Study","Inclusion Criteria:\n\n* Willing and able to provide informed consent (for 16 and 17 year olds: assent and parental\u002F legal guardian consent)\n* Non- or light-smoker (\\< 5 cigarettes a day)\n* Ability to attend appointments in Oxford with reasonable travel costs\n* Ability\u002F willingness to provide GP contact details\n\nExclusion Criteria:\n\n* Past or present DSM-5 axis-I diagnosis (based on SCID results at screening), especially severe psychiatric illness or alcohol or substance dependence\n* First-degree family member with severe psychiatric illness\n* CNS-medication last 6 weeks (including as part of another study)\n* Current blood pressure or other heart medication (especially aliskiren or beta blockers)\n* Diagnosis of intravascular fluid depletion or dehydration\n* Impaired kidney function (based on blood test at screening, cut-off 75 ml\u002Fmin\u002F1.73 m2)\n* Significant hyperkalaemia (level\\>=6mEq\u002FL in the absence of sample haemolysis will be considered significant hyperkalaemia)\n* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F50 mmHg (in accordance with established standard definitions: DOI 10.1186\u002Fs12887-016-0633-7))\n* Body weight below 35kg (as the lower dose of 25mg of losartan only indicated from 35kg)\n* Lifetime history of epilepsy or other neurological disease (e.g. ADHD, autism)\n* Lifetime history of angioedema, renal artery stenosis, valvular heart disease, recurrent postural\u002F orthostatic hypotension\n* Lifetime history ofsystemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Significant loss of hearing that is not corrected with a hearing device Insufficient written and\u002For spoken English skills\n* Women: pregnancy, breast-feeding","16 Years","20 Years",{"count":143,"type":23},60,[62],"This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.",[31],[67,148,149],"anxiety","adolescents","2025-06-12",{"date":152,"type":42},"2025-06-15",{"date":154,"type":42},"2024-03-07",{"date":156,"type":23},"2025-12-31",{"name":48,"class":49},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":50},"100547772","7t-amygdala-and-citalopram-study-100547772","NCT06412315","7T Amygdala and Citalopram Study","The Effects of Citalopram on the Brain's Response to Faces","7TAC","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the research\n* Sufficiently fluent English to understand and complete the task\n\nExclusion Criteria:\n\n* Participants with ferromagnetic objects in their bodies (e.g. metal implants, vessel clips, shrapnel injuries) or with implanted devices which may be damaged by the magnet (e.g. heart pacemakers)\n* Any other MRI contraindication following MRI safety screening\n* History or current significant psychiatric illness (like major depressive disorder)\n* Current or past diagnosis of any significant personality disorder (e.g. borderline personality disorder) according to self-report\n* Diagnosis of attention deficit hyperactive disorder or autistic spectrum disorder that impairs daily functioning, requires pharmacotherapy or in the opinion of the study medic would affect the scientific integrity of the study\n* Currently or within last 3 months taking psychoactive medications (requires further discussion with researcher)\n* Current or within the last 3 months use of medication that might interact with the effects of citalopram or affect the scientific integrity of the study\n* Known contraindication to citalopram including: past allergic reaction to citalopram or any other medicines, diagnosis of a cardiovascular condition, glaucoma, type 1 or type 2 diabetes, diagnosis of epilepsy, previous diagnosis of angle-closure glaucoma, or current use of any other medication whose use interacts with citalopram (according to British National Formulary (BNF) guidance) e.g. associated with prolonged QT-interval\n* Any other current or past medical conditions which in the opinion of the study medic may interfere with the safety of the participant or the scientific integrity of the study including epilepsy\u002Fseizures, brain injury, hepatic or renal disease, diabetes, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions\n* Clinically significant abnormal values for urine drug screen, pulse, and blood pressure measurement (in accordance with Best Practice Guidance 13: 'Non-invasive measurement of blood pressure'). A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures\n* Current alcohol or substance misuse disorder\n* Body Mass Index under 18 and over 30\n* Pregnant or planning a pregnancy, or breast feeding\n* Previously taken part in a study that used similar computer tasks (MRI faces task, emotional test battery) as those in the present study\n* Participation in a study that involves the use of a psychoactive medication or brain stimulation within the last three months\n* Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within last three months\n* Smoking \\> 5 cigarettes per day, or vape a comparable amount (\\> 0.5ml \u002F a quarter of a 2ml vape);\n* Typically drinks \\> 6 caffeinated drinks per day (e.g. tea, coffee, coca cola, Red Bull)\n* Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator",{"count":167,"type":23},50,[89],"The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information.\n\nHealthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.",[31,37,171,103,172],"Mood Disorders","Depression",[174,175,176,31,177,178,179],"Antidepressants","Experimental medicine","Psychopharmacology","fMRI","High field strength fMRI","7 Tesla MRI","2025-02-19",{"date":182,"type":42},"2025-02-21",{"date":184,"type":42},"2025-02-13",{"date":186,"type":23},"2026-10-31",{"name":48,"class":49},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":50},"100564359","early-phase-1-losartan-and-emotional-learning-100564359","NCT06628154","Losartan and Emotional Learning","The Effects of Single-dose Losartan on Cognitive Flexibility and Learning in Healthy Adults: a Randomised Controlled Study","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Aged 18-50 years\n* Score of or below 45 on the Dimensional Anhedonia Rating Scale (DARS; Rizvi et al., 2015)\n* Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires\n* Non- or light-smoker (5 cigarettes a day)\n\nExclusion Criteria:\n\n* Past or present DSM-5 axis-I diagnosis (based on SCID results at screening) other than anxiety disorder, dysthymia or unipolar depression\n* First-degree family member with severe psychiatric illness\n* CNS-medication last 6 weeks (including as part of another study)\n* Current blood pressure or other heart medication (especially aliskiren or beta blockers)\n* Diagnosis of intravascular fluid depletion or dehydration\n* History of angioedema\n* Impaired kidney function (based on self-report)\n* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F50 mmHg (in accordance with established standard definitions: DOI 10.1186\u002Fs12887-016-0633-7))\n* Lifetime history of epilepsy or other neurological disease (e.g. autism, ADHD)\n* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study\n* Significant loss of hearing that is not corrected with a hearing device\n* Women: pregnancy, breast-feeding","50 Years",{"count":143,"type":23},[62],"This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in healthy volunteers.",[31],[67,201,148,202],"reward","depression","2024-10-02",{"date":205,"type":42},"2024-10-04",{"date":207,"type":42},"2024-08-14",{"date":209,"type":23},"2025-07",{"name":48,"class":49}]